Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-90014496 · 1 trial · 3 indications
Occurrence of any AEs, including dose limiting toxicities (DLTs).
Overall response is defined as a PR or CR at any point between the time of JNJ-90014496 infusion until PD or start of subsequent anti-lymphoma therapy, whichever occurs first (per Lugano 2014 guidelines).
| Arm | Type | Description |
|---|---|---|
| JNJ-90014496 | EXPERIMENTAL | Participants will receive intravenous (IV) infusion of autologous JNJ-90014496. The study is no longer enrolling. |
| Name | Type | Description |
|---|---|---|
| JNJ-90014496 | BIOLOGICAL | JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19. |
Inclusion Criteria: * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive * Must meet the indications for each subtype in Phase 1b as specified in ...
JNJ-90014496 is an investigational monoclonal antibody being studied for the treatment of B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. It is not approved for any indication and remains in clinical development. The Phase 1 study enrolls adults with these lymphoma subtypes.
JNJ-90014496 targets CD19, a protein expressed on the surface of B cells. By binding CD19, the antibody is designed to engage the immune system against malignant B cells. This CD19-directed approach is being evaluated in B-cell non-Hodgkin lymphoma.
JNJ-90014496 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company is the sponsor of the ongoing Phase 1 study in B-cell non-Hodgkin lymphoma.
JNJ-90014496 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The single ongoing trial is a Phase 1 study in participants with B-cell non-Hodgkin lymphoma.
JNJ-90014496 is being evaluated in one active clinical trial, NCT05421663, titled A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma. The Phase 1 trial has an estimated enrollment of 166 adults and is currently active but not recruiting. It is conducted in the United States, Australia, Canada, Denmark, Netherlands, South Korea, Spain, and the United Kingdom.